UCERIS (budesonide ER)
SELF ADMINISTRATION – ORAL
Indications for Prior Authorization:
- Approvable for induction of remission in patients with active, mild to moderate ulcerative colitis
Patients must meet the following criteria for the indication(s) above:
- Diagnosis of ulcerative colitis
The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P&T Committee:
- All non-FDA approved uses not listed in the approved indications
Recommended Dosing:
- 9 mg once daily
Duration:
- Maximum duration of therapy is 8 weeks
Approval:
Eight weeks
Last review date: December 3, 2013